• Our Company
    • About Us
    • About Xanamem®
    • Our Team
    • Recent Annual Reports
    • Our Strategic Priorities
    • Corporate Governance
  • Xanamem®
    • The Cortisol Hypothesis
    • Mechanism of Action
    • Publications
  • Clinical Trials
    • Clinical Development Pipeline
      • Cognitive Impairment in early Alzheimer’s Disease
      • Cognitive Impairment in MDD
      • Anxiety, sleep & behavioral problems in Fragile X Syndrome
    • Patient Portal
    • Participate in clinical trials
      • The XanaCIDD Depression Clinical Trial
      • The XanaMIA Phase 2b Alzheimer’s Trial
    • Publications
  • Investor Centre
    • Share Price
    • ASX Announcements
    • Corporate Presentations
    • Analyst Reports
    • Financial Results Centre
    • Annual General Meeting
    • General Meeting
    • Financial Calendar
    • Right to Receive Documents
    • Frequently Asked Questions
    • Investor Contacts
  • News
  • Contact Us